A novel intramuscular bivalent norovirus viruslike particle vaccine candidate-reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults

Journal of Infectious Diseases

Volumn 210, Issue 11, 2014, Pages 1763-1771

  Treanor, John J ^a   Atmar, Robert L ^b   Frey, Sharon E ^c   Gormley, Robert ^d   Chen, Wilbur H ^e   Ferreira, Jennifer ^f   Goodwin, Robert ^g   Borkowski, Astrid ^h   Clemens, Ralf ^h   Mendelman, Paul M ^g  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NAVAL MEDICAL RESEARCH CENTER   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f EMMES   (United States)

^g Takeda Vaccines   (United States)

^h Takeda Vaccines   (Switzerland)

Author keywords

Gastroenteritis; Norovirus; Vaccine; Virus like particle

Indexed keywords

BLOOD GROUP ANTIGEN; HISTOBLOOD GROUP ANTIGEN; PLACEBO; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ADULT; ADVERSE OUTCOME; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GROUPS BY AGE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE PAIN; MALE; MIDDLE AGED; NORMAL HUMAN; NOROVIRUS INFECTION; OUTCOME ASSESSMENT; PHARMACOLOGICAL BLOCKING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; ADOLESCENT; BLOOD; CALICIVIRIDAE INFECTIONS; CLINICAL TRIAL; FOLLOW UP; GASTROENTERITIS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MULTICENTER STUDY; NOROVIRUS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CALICIVIRIDAE INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GASTROENTERITIS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NOROVIRUS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES; YOUNG ADULT;

EID: 84920557982     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu337     Document Type: Article

References (16)

1. Lopman BA, Hall AJ, Curns AT, Parashar UD. Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996-2007. Clin Infect Dis 2011; 52:466-74.
2. Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of Clostridium difficile and Norovirus among gastroenteritis-associated deaths in the United States 199-2007. Clin Infect Dis 2012; 55:213-23.
3. Hall AJ, Lopman BA, Payne DC, et al. Norovirus disease in the United States. Emerg Infect Dis 2013; 19:1198-205.
4. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parashar UD. Systematic literature review of role of Noroviruses in sporadic gastroenteritis. Emerg Infect Dis 2008; 14:1224-31.
5. Tacket CO, Sztein MB, Losonsky G, Wasserman S, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108:241-7.
6. El-Kamary SS, Pasetti MF, Mendelman PM, et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010; 202:1649-58.
7. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 2011; 365:2178-87.
8. Parra GI, Bok K, Taylor R, et al. Immunogenicty and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 2012; 30:3580-6.
9. Graham DY, Jiang X, Tanaka T, Opekun AR, Madore HP, Estes MK. Norwalk virus infection of volunteers: new insights based on improved assays. J Infect Dis 1994; 170:34-43.
10. Kavanagh O, Estes MK, Reeck A, et al. Serologic responses to experimental norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin Vac Immunol 2011; 18:1187-90.
11. Reeck A, Kavanagh O, Estes MK, et al. Serological correlate of protection against Norovirus-induced gastroenteritis. J Infect Dis 2010; 202:1212-8.
12. LoBue AD, Lindesmith L, Yount B, et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 2006; 24:5220-34.
13. Hutson AM, Airaud F, LePendu J, Estes MK, Atmar RL. Norwalk virus infection associates with secretor status genotyped from sera. J Med Virol 2005; 77:116-20.
14. Frenck R, Bernstein DI, Xia M, et al. Predicting susceptibility to Norovirus GII.4 by use of a challenge model involving humans. J Infect Dis 2012; 206:1386-93.
15. Levie K, Gjorup I, Skinhoj P, Stoffel M. A 2-dose regimen of a crcombinant hepatitis B vaccine with the immune stimulant ASO4 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand J Infect Dis 2002; 34:610-4.
16. Romanosski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/AS0-4-adjuvanted vaccine admi9nistered as a 2-dose schedule compared t the licensed 3-dose schedule: results from a randomized study Human. Vaccines 2011; 7:1374-86.